抗CD19 CAR-T桥接异基因造血干细胞移植治疗难治B淋巴细胞白血病的安全性与疗效
该回顾性研究纳入10例抗CD19 CAR-T治疗后达MRD阴性的难治B淋巴细胞白血病患者,序贯allo-HSCT。10例均获完全供者植入,中位随访262天,预期1年OS为(90.0±1.0)%,DFS为(85.7±1.3)%,提示该方案可行且结局良好。
要点
- 抗CD19 CAR-T后达MRD阴性再桥接allo-HSCT,10例均获完全植入。
- 中性粒细胞植入中位15天,血小板植入中位19天。
- 预期1年OS为(90.0±1.0)%,DFS为(85.7±1.3)%。
核心结论
- 抗CD19 CAR-T细胞治疗达深度缓解后序贯allo-HSCT可作为难治B淋巴细胞白血病患者的可选治疗方案。
研究设计与样本
- 回顾性分析2017年11月至2019年3月河南省肿瘤医院收治的10例难治B淋巴细胞白血病患者。
- 患者均经抗CD19 CAR-T细胞治疗达MRD阴性后序贯allo-HSCT。
主要发现
- 10例中男5例、女5例,中位年龄23.5(10~31)岁,难治急性B淋巴细胞白血病9例、慢性淋巴细胞白血病1例。
- 亲缘全相合移植2例、亲缘单倍型移植8例,CAR-T达深度缓解至allo-HSCT中位时间32.5(20~60)d。
- 10例均获造血重建,中性粒细胞植入中位15(15~21)d,血小板植入中位19(17~30)d。
- 8例(80%)移植过程中出现发热,Ⅱ度aGVHD 2例、Ⅲ度aGVHD 1例,9例存活者中8例出现局限性慢性GVHD。
- 中位随访262(150~540)d,预期1年总生存率为(90.0±1.0)%,无病生存率为(85.7±1.3)%。
关键数值与推荐
- 10例患者抗CD19 CAR-T细胞治疗后第30天及移植前评估MRD均为阴性。
- 预处理过程中10例均未出现肝静脉闭塞病及出血性膀胱炎。
- 1例出现渗漏综合征,经限制入量、补充白蛋白及利尿等治疗后好转。
临床怎么用
- 对难治B淋巴细胞白血病,可考虑抗CD19 CAR-T达MRD阴性后桥接allo-HSCT。
- 移植后需监测aGVHD与cGVHD,以及发热和渗漏综合征等并发症。
局限性
- 本研究为单中心回顾性分析,样本量仅10例。
- 随访时间较短,中位随访262(150~540)d。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the efficacy and side effects of anti-CD19 CAR-T cell bridging to allogeneic hematopoietic stem cell transplantation (allo-HSCT) regimen for refractory B-lymphoblastic leukemia. Methods: 10 patients with refractory B-lymphoblastic leukemia with minimal residual disease (MRD) negative after anti-CD19 CAR-T cell treatment, then bridging to allo-HSCT from November 2017 to March 2019 in the Affiliated Cancer Hospital of Zhengzhou University were retrospectively analyzed. Results: ①Among 10 patients, 5 were males and 5 females, with a median age of 23.6 (10-31) years. 9 patients were diagnosed refractory acute lymphoblastic leukemia and the other one was chronic lymphoblastic leukemia. 10 patients reached MRD negative 30 days after anti-CD19 CAR-T cell. ②The donors were identical sibling (2 cases) and haploidentical family member (8 cases) . The median time from MRD negative after CAR-T treatment to transplantation were 32.5 (20-60) days. ③10 patients obtained complete haploidentical engraftment. The median time of neutrophil implantation was 15 (15-21) days, and 19 (17-30) days of platelet implantation. ④ After conditioning, no hepatic venoocclusive disease and hemorrhagic cystitis occurred. One patient had leakage syndrome and got improved after intervention such as limited water entry, albumin supplementation and diuresis. 8 (80%) patients had fever, 2 cases experienced acute graft-versus-host disease (GVHD) grade Ⅱ, 1 case with aGVHD grade Ⅲ. Among 9 survivals, localized chronic GVHD occurred in 8 patients. ⑤The median follow-up was 262 (150-540) days and the estimated 1-years overall survivaln (OS) and disease free survival (DFS) were (90.0±1.0) % and (85.7±1.3) %, respectively. Conclusion: Anti-CD19 CAR-T cell bridging to allo-HSCT regimen is a feasible choice with favorable outcome for refractory B-lymphoblastic leukemia. 目的: 探讨抗CD19 CAR-T细胞治疗达深度缓解后序贯异基因造血干细胞移植(allo-HSCT)治疗难治B淋巴细胞白血病的疗效及不良反应。 方法: 回顾性分析2017年11月至2019年3月河南省肿瘤医院收治的10例抗CD19 CAR-T细胞治疗达深度缓解后序贯allo-HSCT难治B淋巴细胞白血病患者的临床资料。 结果: ①10例患者中,男5例,女5例,中位年龄23.5(10~31)岁,其中难治急性B淋巴细胞白血病(B-ALL)9例,慢性淋巴细胞白血病(CLL)1例。10例患者抗CD19 CAR-T细胞治疗后第30天及移植前评估微小残留病(MRD)均为阴性。②亲缘全相合移植2例,亲缘单倍型移植8例,抗CD19 CAR-T细胞治疗获得深度缓解至allo-HSCT中位时间为32.5(20~60)d。③10例患者获得造血重建,中性粒细胞植入中位时间为15(15~21)d,血小板植入中位时间为19(17~30)d。④预处理过程中,10例患者均未出现肝静脉闭塞病及出血性膀胱炎。1例患者出现渗漏综合征,予以限制入量、补充白蛋白及利尿等治疗后好转。移植过程中8例(80%)出现发热,均经抗感染治疗后好转。发生Ⅱ度急性移植物抗宿主病(aGVHD)2例,Ⅲ度aGVHD 1例;至随访截止9例存活患者中8例出现局限性慢性移植物抗宿主病。⑤中位随访262(150~540)d,预期1年总生存率为(90.0±1.0)%,无病生存率为(85.7±1.3)%。 结论: 抗CD19 CAR-T细胞治疗达深度缓解后序贯allo-HSCT可作为难治B淋巴细胞白血病患者的可选治疗方案。.
引用
- Ai H, Yin QS, Wang Q, et al. [Safety and efficacy of patients with refractory B-lymphoblastic leukemia treated with anti-CD19 CAR-T cell bridging to allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32311895. doi:10.3760/cma.j.issn.0253-2727.2020.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。